Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus high-dose antithymocyte globulin plus cyclosporine in transfusion-dependent non-severe aplastic anemia
ChiCTR2100044033Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2019
- Modality
- Small Molecules, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin and cyclosporine in aplastic anemia (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Basic cure rate, Remission rate and 1 more. Started Jul 2019; status: recruiting.
02
Drugs
antithymocyte globulincyclosporine
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2100044033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044033.